Correction to: Nature Communications https://doi.org/10.1038/s41467-022-35470-4, published online 20 December 2022
In the version of this article initially published, due to a figure assembly error, in Fig. 6c, upper panel, the representative H&E staining image for LT3 was inadvertently chosen from the Saline group. This correction does not affect the study’s results or conclusions. The figure is now amended in the HTML and PDF versions of the article.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Chen, K., Cheong, L.Y., Gao, Y. et al. Author Correction: Adipose-targeted triiodothyronine therapy counteracts obesity-related metabolic complications and atherosclerosis with negligible side effects. Nat Commun 17, 3447 (2026). https://doi.org/10.1038/s41467-026-71985-w
Published:
Version of record:
DOI: https://doi.org/10.1038/s41467-026-71985-w
